Goldman Sachs Portfolio holdings
Goldman Sachs, founded in 1869 by Marcus Goldman and later joined by Samuel Sachs, is a premier global investment bank headquartered in New York City, renowned for its influential role in financial markets. The firm provides a wide range of services, including investment banking (mergers, acquisitions, and underwriting), securities trading, asset management, and consumer banking through its Marcus platform, catering to corporations, governments, institutions, and high-net-worth individuals. Known for its elite status on Wall Street, Goldman Sachs has a history of navigating major economic events, from the Great Depression to the 2008 financial crisis, where it played a controversial yet pivotal role. With a strong emphasis on innovation and a global footprint, it manages billions in assets and remains a powerhouse in shaping economic policy and market trends.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$1.04B |
| 2 |
Gaotu Techedu
GOTU
|
+$1.03B |
| 3 |
Visa
V
|
+$749M |
| 4 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$517M |
| 5 |
State Street SPDR S&P Biotech ETF
XBI
|
+$515M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$4.43B |
| 2 |
Invesco QQQ Trust
QQQ
|
+$2.58B |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$759M |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$643M |
| 5 |
VAR
Varian Medical Systems, Inc.
VAR
|
+$595M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.23% |
| 2 | Consumer Discretionary | 8.46% |
| 3 | Healthcare | 7.67% |
| 4 | Financials | 7.46% |
| 5 | Communication Services | 6.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3976
SI-BONE Inc
SIBN
$834M
| $1.29M | ﹤0.01% |
43,109
+23,847
| +124% | +$581K |
|
3977
Fidelity Momentum Factor ETF
FDMO
$958M
| $1.29M | ﹤0.01% |
29,133
| – | – |
|
3978
PUT
XPeng
XPEV
$11.6B
| $1.28M | ﹤0.01% |
+30,000
| New | +$1.1M |
|
3979
Manitowoc
MTW
$675M
| $1.28M | ﹤0.01% |
96,333
+1,382
| +1% | +$14.7K |
|
|
APLT
3980
DELISTED
Applied Therapeutics
APLT
| $1.28M | ﹤0.01% |
58,159
+45,711
| +367% | +$952K |
|
|
JIH
3981
DELISTED
Juniper Industrial Holdings, Inc.
JIH
| $1.28M | ﹤0.01% |
119,552
+80,000
| +202% | +$825K |
|
|
SYRS
3982
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $1.28M | ﹤0.01% |
11,788
+2,581
| +28% | +$236K |
|
3983
Albertsons Companies
ACI
$5.83B
| $1.28M | ﹤0.01% |
72,640
-252,748
| -78% | -$3.83M |
|
|
ARNA
3984
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $1.27M | ﹤0.01% |
16,600
-2,000
| -11% | -$150K |
|
|
KRON
3985
DELISTED
Kronos Bio
KRON
| $1.27M | ﹤0.01% |
+42,531
| New | +$1.33M |
|
3986
CALL
NovoCure
NVCR
$1.91B
| $1.26M | ﹤0.01% |
7,300
| – | – |
|
3987
W&T Offshore
WTI
$518M
| $1.26M | ﹤0.01% |
581,722
-10,400
| -2% | -$20K |
|
3988
CALL
Ares Management
ARES
$30.9B
| $1.26M | ﹤0.01% |
26,800
| – | – |
|
|
ORTX
3989
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $1.26M | ﹤0.01% |
29,156
+23,323
| +400% | +$1.04M |
|
3990
PUT
Capital One
COF
$134B
| $1.25M | ﹤0.01% |
12,700
-219,200
| -95% | -$18.6M |
|
3991
Invesco FTSE RAFI US 1000 ETF
PRF
$10B
| $1.25M | ﹤0.01% |
47,020
-470
| -1% | -$11.7K |
|
3992
Gorman-Rupp
GRC
$2.21B
| $1.25M | ﹤0.01% |
38,589
+31,614
| +453% | +$1.05M |
|
3993
Pure Cycle
PCYO
$261M
| $1.25M | ﹤0.01% |
111,435
-7,561
| -6% | -$75.1K |
|
3994
Midland States Bancorp
MSBI
$695M
| $1.25M | ﹤0.01% |
69,753
-26,180
| -27% | -$427K |
|
3995
Talos Energy
TALO
$2.4B
| $1.24M | ﹤0.01% |
151,032
-88,190
| -37% | -$686K |
|
|
DGNS
3996
DELISTED
Dragoneer Growth Opportunities Corp. II Class A Ordinary Shares
DGNS
| $1.24M | ﹤0.01% |
+108,946
| New | +$1.23M |
|
3997
iShares MSCI USA Value Factor ETF
VLUE
$9.44B
| $1.24M | ﹤0.01% |
14,259
+149
| +1% | +$12.1K |
|
3998
CALL
BioXcel Therapeutics
BTAI
$27.8M
| $1.24M | ﹤0.01% |
1,675
+237
| +16% | +$185K |
|
|
DSKE
3999
DELISTED
Daseke, Inc. Common Stock
DSKE
| $1.24M | ﹤0.01% |
212,982
+7,997
| +4% | +$51K |
|
|
PRVB
4000
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $1.24M | ﹤0.01% |
72,989
-60,928
| -45% | -$913K |
|
Similar funds
Goldman Sachs's Q4 2020 Portfolio in Review
As of Q4 2020, Goldman Sachs held 5,916 positions worth $389B, up 10% from $352B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Goldman Sachs withdrew a net $17.4B in Q4 2020, closing 466 positions and reducing 2,520 holdings. Its most notable exit was Immunomedics Inc, an estimated $418M position sold in full.
By sector, the portfolio is most concentrated in Technology at 14% of assets, down from 14% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Goldman Sachs opened a new position in Chindata Group Holdings Limited American Depositary Shares worth $290M.
- Goldman Sachs's largest Q4 2020 buy was Chindata Group Holdings Limited American Depositary Shares: 12,107,899 shares worth $290M.
- Goldman Sachs added most to iShares iBoxx $ Investment Grade Corporate Bond ETF in Q4 2020, an estimated $1.04B increase.
- Goldman Sachs's biggest Q4 2020 reduction was Tesla, cutting an estimated $4.43B.
- Goldman Sachs fully exited Immunomedics Inc in Q4 2020, selling an estimated $418M.
- Goldman Sachs's ten largest holdings make up 20% of its $389B portfolio in Q4 2020.
- Goldman Sachs opened 643 new positions and closed 466 in Q4 2020.
- Goldman Sachs's portfolio value rose 10% quarter-over-quarter to $389B.
Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.